

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version 2.0      Revision Date: 06.04.2024      SDS Number: 2160714-00015      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

### Section 1: Identification

**Product identifier** : Finasteride (3.25%) Formulation

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

#### Manufacturer or supplier's details

Company : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : +1-551-430-6000  
Emergency telephone number : +1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

---

### Section 2: Hazard identification

#### Classification of the substance or mixture

Reproductive toxicity : Category 1B  
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Testis)  
Long-term (chronic) aquatic hazard : Category 2

#### GHS Label elements, including precautionary statements

Hazard pictograms :

Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.

---

## Finasteride (3.25%) Formulation

Version 2.0	Revision Date: 06.04.2024	SDS Number: 2160714-00015	Date of last issue: 30.09.2023 Date of first issue: 09.11.2017
----------------	------------------------------	------------------------------	---

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 1 -< 10
Starch	9005-25-8	>= 1 -< 10
Finasteride	98319-26-7	>= 2.5 -< 10

**Section 4: First-aid measures****Description of necessary first-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed**

Risks : May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Indication of any immediate medical attention and special treatment needed**

Treatment : Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures****Extinguishing media**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

**Special hazards arising from the substance or mixture**

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

**Special protective actions for fire-fighters**

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**Section 6: Accidental release measures****Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

**Methods and materials for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Section 7: Handling and storage****Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust, fume, gas, mist, vapours or spray.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage, including any incompatibilities**

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Finasteride (3.25%) Formulation

Version 2.0      Revision Date: 06.04.2024      SDS Number: 2160714-00015      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

## Section 8: Exposure controls/personal protection

## Control parameters

## Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Finasteride	98319-26-7	TWA	0.5 µg/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	5 µg/100 cm <sup>2</sup>	Internal

**Appropriate engineering control measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Individual protection measures, such as personal protective equipment (PPE)**

**Eye/face protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version 2.0      Revision Date: 06.04.2024      SDS Number: 2160714-00015      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

---

### Section 9: Physical and chemical properties

Appearance : solid

Colour : blue

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics	:	
Particle size	:	No data available

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Information on likely routes of exposure	:	Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	--

**Components:****Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

**Starch:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

**Finasteride (3.25%) Formulation**

Version 2.0      Revision Date: 06.04.2024      SDS Number: 2160714-00015      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

**Finasteride:**

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg  
LD50 (Mouse): 486 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Finasteride:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Starch:**

Species : Rabbit  
Result : No eye irritation

**Finasteride:**

Species : Rabbit  
Remarks : slight irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Starch:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
	Species: Mouse
	Application Route: Ingestion
	Result: negative

**Starch:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative

**Finasteride:**

Genotoxicity in vitro	: Test Type: Chromosome aberration test in vitro
	Result: positive
	Test Type: In vitro mammalian cell gene mutation test
	Result: negative
	Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Alkaline elution assay
	Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Application Route: Oral
	Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

**Finasteride:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
	: 160 mg/kg body weight
Result	: negative

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

Target Organs	: Testes
Remarks	: Benign tumor(s)

Species	: Mouse
Application Route	: Ingestion
Exposure time	: 19 month(s)
Result	: negative
Target Organs	: Testes
Remarks	: Benign tumor(s)

**Reproductive toxicity**

May damage the unborn child.

**Components:****Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

**Finasteride:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Oral Fertility: NOAEL: 80 mg/kg body weight Result: No effects on fertility
	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Fertility: LOAEL: 80 mg/kg body weight Result: positive Remarks: There is no evidence that these findings are relevant to humans.
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Developmental Toxicity: LOAEL: 0.003 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects.
	: Test Type: Embryo-foetal development Species: Monkey Application Route: Ingestion Developmental Toxicity: LOAEL: 2 mg/kg body weight

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

Result: Teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.

**Components:****Finasteride:**

Exposure routes	: Ingestion
Target Organs	: Testis
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

**Starch:**

Species	: Rat
NOAEL	: >= 2,000 mg/kg
Application Route	: Skin contact
Exposure time	: 28 Days
Method	: OECD Test Guideline 410

**Finasteride:**

Species	: Rat
NOAEL	: 20 mg/kg
LOAEL	: 40 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Target Organs	: Testis

Species	: Dog
NOAEL	: 45 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Target Organs	: Testis

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Finasteride:

Ingestion	:	Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash
-----------	---	---

---

## Section 12: Ecological information

### Toxicity

#### Components:

#### Cellulose:

Toxicity to fish	:	LC50 ( <i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

#### Finasteride:

Toxicity to fish	:	LC50 ( <i>Oncorhynchus mykiss</i> (rainbow trout)): 20.4 mg/l Exposure time: 96 h Method: FDA 4.11
Toxicity to daphnia and other aquatic invertebrates	:	EC50 ( <i>Daphnia magna</i> (Water flea)): 17.8 mg/l Exposure time: 48 h Method: FDA 4.08
Toxicity to algae/aquatic plants	:	NOEC ( <i>Pseudokirchneriella subcapitata</i> (green algae)): 49 mg/l Exposure time: 14 h Method: FDA 4.01
Toxicity to fish (Chronic toxicity)	:	NOEC ( <i>Oryzias latipes</i> (Orange-red killifish)): 0.05 mg/l Exposure time: 105 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC ( <i>Daphnia magna</i> (Water flea)): 0.12 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	:	1

### Persistence and degradability

#### Components:

#### Cellulose:

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version 2.0      Revision Date: 06.04.2024      SDS Number: 2160714-00015      Date of last issue: 30.09.2023  
Date of first issue: 09.11.2017

---

### Finasteride:

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 7 d  
Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)  
Method: FDA 3.09

### Bioaccumulative potential

### Components:

#### Finasteride:

Partition coefficient: n-octanol/water : log Pow: 3.57

#### Mobility in soil

No data available

#### Other adverse effects

No data available

---

## Section 13: Disposal considerations

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## Section 14: Transport information

### International Regulations

#### UNRTDG

UN number : UN 3077  
UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Finasteride)

Transport hazard class(es) : 9  
Packing group : III  
Labels : 9  
Environmental hazards : yes

#### IATA-DGR

UN/ID No. : UN 3077  
UN proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Finasteride)

Transport hazard class(es) : 9  
Packing group : III

---

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Finasteride)  
Transport hazard class(es) : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## Section 15: Regulatory information

### Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## Section 16: Other information

Revision Date : 06.04.2024

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

# SAFETY DATA SHEET



## Finasteride (3.25%) Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
2.0	06.04.2024	2160714-00015	Date of first issue: 09.11.2017

---

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN